Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other …

myelodysplasia
mycophenolate
donor lymphocyte infusion
myeloid malignancy
thrombocytopenia
  • 0 views
  • 21 Apr, 2022
  • 1 location
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation (CTL-DP 01)

mismatched of HLA class II could induce a selective GVL reactivity without GVHD. HLA-DP-expressing B cell and myeloid malignancies can be recognized and lysed by HLA-DP-specific T cells. The majority

immunosuppressant
leukemia
hodgkin's disease
granulocyte colony stimulating factor
recurrent disease
  • 0 views
  • 04 Oct, 2022
  • 1 location
Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

This study aims to evaluate the effectiveness and safety of Venetoclax and Decitabin based conditioning regimen followed with post-HSCT Decitabin maintenance therapy in TP53 mutant AML/MDS Patients.

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Background Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective To see if stem cell transplants can be …

mycophenolate mofetil
x-rays
cyclophosphamide
allogeneic hematopoietic stem cell transplant
fludarabine
  • 0 views
  • 21 Oct, 2022
  • 1 location
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study …

  • 0 views
  • 27 Oct, 2022
  • 1 location
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

blast cells
bone marrow procedure
blood transfusion
azacitidine
cytopenia
  • 7 views
  • 04 Oct, 2022
  • 13 locations
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

bone marrow procedure
colony stimulating factor
blood transfusion
granulocyte colony stimulating factor
azacitidine
  • 4 views
  • 04 Oct, 2022
  • 4 locations
The Myeloid Neoplasms Biology and Outcome Project

The Myeloid Neoplasms Biology and Outcome Project (MyBOP) aims to establish a registry study for patients with myeloid neoplasms. It integrates clinical data, biological samples, socio

  • 0 views
  • 17 Oct, 2021
  • 1 location
German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)

To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 classification) in participating centers To store samples from

  • 5 views
  • 24 Jan, 2021
  • 33 locations
Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)

Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >99% of those …

  • 0 views
  • 07 Oct, 2022
  • 1 location